Cholesterol potentiates ABCG2 activity in a heterologous expression system: Improved in vitro model to study function of human ABCG2

Journal of Pharmacology and Experimental Therapeutics

Volumn 321, Issue 3, 2007, Pages 1085-1094

  Pal A ^a   Mehn D ^a   Molnar E ^a   Gedey, S ^a   Meszaros P ^a   Nagy, T ^a   Glavinas, H ^a   Janaky T ^b   Von Richter, O ^c   Bathori G ^a   Szente, L ^d   Krajcsi, Peter ^a,e  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c ALTANA PHARMA AG   (Germany)

^d CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^e Rational Drug Design Laboratories   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CHOLESTEROL; PRAZOSIN; SALAZOSULFAPYRIDINE; TOPOTECAN;

ARTICLE; CELL MEMBRANE; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; GENE OVEREXPRESSION; HETEROLOGOUS EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; INSECT CELL; LIPID COMPOSITION; MEMBRANE VESICLE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BACULOVIRIDAE; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CELL MEMBRANE; CHOLESTEROL; ESTRONE; GLYCOSYLATION; HUMANS; KINETICS; METHOTREXATE; NEOPLASM PROTEINS; PEPTIDE-N4-(N-ACETYL-BETA-GLUCOSAMINYL) ASPARAGINE AMIDASE; PHARMACEUTICAL PREPARATIONS; PRAZOSIN; SPODOPTERA; SULFASALAZINE; TOPOTECAN;

EID: 34248530310     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.119289     Document Type: Article

References (40)

1. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, Schellens JH, Koomen GJ, and Schinkel AH (2002) Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 1:417-425.
2. Arima H, Yunomae K, Morikawa T, Hirayama F, and Uekama K (2004) Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-beta-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers. Pharm Res 21:625-634.
3. Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matko J, and Szabo G (2004) Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A 61:105-116.
4. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, and Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65:2577-2582.
5. Contreras JA, Castro M, Bocos C, Herrera E, and Lasuncion MA (1992) Combination of an enzymatic method and HPLC for the quantitation of cholesterol in cultured cells. J Lipid Res 33:931-936.
6. Diop NK and Hrycyna CA (2005) N-Linked glycosylation of the human ABC transporter ABCG2 on asparagine 596 is not essential for expression, transport activity, or trafficking to the plasma membrane. Biochemistry 44:5420-5429.
7. Ebert B, Seidel A, and Lampen A (2005) Identification of BCRP as transporter of benzopyrene conjugates metabolically formed in Caco-2 cells and its induction by Ah-receptor agonists. Carcinogenesis 26:1754-1763.
8. Gao M, Loe DW, Grant CE, Cole SP, and Deeley RG (1996) Reconstitution of ATP-dependent leukotriene C4 transport by Co-expression of both half-molecules of human multidrug resistance protein in insect cells. J Biol Chem 271:27782-27787.
9. Garrigues A, Escargueil AE, and Orlowski S (2002) The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci USA 99:10347-10352.
10. Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, Mazane A, Coleman AW, Rigal D, and Baggetto LG (2005) Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Biochemistry 44:4499-4509.
11. Gimpl G, Klein U, Reilander H, and Fahrenholz F (1995) Expression of the human oxytocin receptor in baculovirus-infected insect cells: high-affinity binding is induced by a cholesterol-cyclodextrin complex. Biochemistry 34:13794-13801.
12. Glavinas H, Krajcsi P, Cserepes J, and Sarkadi B (2004) The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 1:27-42.
13. Han B and Zhang JT (2004) Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 4:31-42.
14. Honjo Y, Hrycyna CA, Yan QW, Medina-Perez WY, Robey RW, van de Laar A, Litman T, Dean M, and Bates SE (2001) Acquired mutations in the MXR/BCRP/ ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. Cancer Res 61:6635-6639.
15. Ishikawa T, Kasamatsu S, Hagiwara Y, Mitomo H, Kato R, and Sumino Y (2003) Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab Pharmacokinet 18:194-202.
16. Janvilisri T, Venter H, Shahi S, Reuter G, Balakrishnan L, and van Veen HW (2003) Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem 278:20645-20651.
17. Jonker JW, Merino G, Musters S, van Herwaarden AE, Bolscher E, Wagenaar E, Mesman E, Dale TC, and Schinkel AH (2005) The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11:127-129.
18. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
19. Krishnamurthy P and Schuetz JD (2005) The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival. Biometals 18:349-358.
20. Le Goff W, Settle M, Greene DJ, Morton RE, and Smith JD (2006) Reevaluation of the role of the multidrug-resistant P-glycoprotein in cellular cholesterol homeostasis. J Lipid Res 47:51-58.
21. Leier I, Jedlitschky G, Buchholz U, and Keppler D (1994) Characterization of the ATP-dependent leukotriene C4 export carrier in mastocytoma cells. Eur J Biochem 220:599-606.
22. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
23. Mao Q and Unadkat JD (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-133.
24. Mohrmann K, van Eijndhoven MA, Schinkel AH, and Schellens JH (2005) Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemother Pharmacol 56:344-350.
25. Neubig RR, Spedding M, Kenakin T, and Christopoulos A (2003) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification: XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55:597-606.
26. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, and Sarkadi B (2001) Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 285:111-117.
27. Ozvegy C, Varadi A, and Sarkadi B (2002) Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter: modulation of substrate specificity by a point mutation. J Biol Chem 277:47980-47990.
28. Piel G, Piette M, Barillaro V, Castagne D, Evrard B, and Delattre L (2006) Betamethasone-in-cyclodextrin-in-liposome: the effect of cyclodextrins on encapsulation efficiency and release kinetics. Int J Pharm 312:75-82.
29. Polli JW, Baughman TM, Humphreys JE, Jordan KH, Mote AL, Webster LO, Barnaby RJ, Vitulli G, Bertolotti L, Read KD, et al. (2004) The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the Pglycoprotein and breast cancer resistance protein efflux transporters. Drug Metab Dispos 32:722-726.
30. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246.
31. Sarkadi B, Price EM, Boucher RC, Germann UA, and Scarborough GA (1992) Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 267:4854-4858.
32. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118:422-430.
33. Tietz P, Jefferson J, Pagano R, and Larusso NF (2005) Membrane microdomains in hepatocytes: potential target areas for proteins involved in canalicular bile secretion. J Lipid Res 46:1426-1432.
34. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, Schalkwijk CG, Scheffer GL, Scheper RJ, and Jansen G (2004) Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 63:138-143.
35. Wang E, Casciano CN, Clement RP, and Johnson WW (2000) Cholesterol interaction with the daunorubicin binding site of P-glycoprotein. Biochem Biophys Res Commun 276:909-916.
36. Wang N, Lan D, Chen W, Matsuura F, and Tall AR (2004) ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 101:9774-9779.
37. Xiao Y, Davidson R, Smith A, Pereira D, Zhao S, Soglia J, Gebhard D, de Morais S, and Duignan DB (2006) A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line. Mol Pharm 3:45-54.
38. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, and Hobbs HH (2002) Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 99:16237-16242.
39. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, and Ware JA (2006) Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 3:55-61.
40. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, and Brouwer KL (2006) The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 70:2127-2133.